News

HDA UK Media And Political Bulletin – 10 November 2017

Media and Political Bulletin

10 November 2017

Media Summary

EFPIA urges co-operation to protect patients post Brexit

PharmaTimes, Selina McKee, 9 November 2017

 

PharmaTimes reports on the findings of the survey by the European Federation of Pharmaceutical Industries and Associations of its members, in which it has been revealed that nearly half of members are expecting trade delays if the UK and Europe fail to reach a deal for Brexit.

To prevent such delays, which is critical for patients to access their medicines, the Association has stressed that the EU and UK should ‘agree a comprehensive agreement that ensures maximum alignment between EU and UK pharmaceutical laws’.

The findings of this EFPIA survey were also reported in The Times.

 

Parliamentary Coverage

 

There is no Parliamentary coverage today.

 

Full Coverage

EFPIA urges co-operation to protect patients post Brexit

PharmaTimes, Selina McKee, 9 November 2017

 

Nearly half (45 percent) of members of the European Federation of Pharmaceutical Industries and Associations members are expecting trade delays if the UK and Europe fail to reach a deal for Brexit.

To prevent such delays, which is critical for patients to access their medicines, the EU and UK should “agree a comprehensive agreement that ensures maximum alignment between EU and UK pharmaceutical laws,” the Association stressed.

The call comes after EFPIA research highlighted that more 2,600 final medicine products have some stage of manufacture based in the UK, that 45 million patient packs are supplied from the UK to other EU-27/EEA countries each month, and that over 37 million patient packs are supplied from the EU-27/EEA to the UK each month.

Additionally, more than 12,000 centrally authorised Marketing Authorisations (MAs) for medicines will require separate approval in the UK in order for the medicine to be prescribed to patients. Around 17 percent of centralised MAs are held in the UK.

Also, there are over 1,500 clinical trials being conducted in multiple EU member states that have a UK-based sponsor, over 50 percent of which are scheduled to continue beyond March 2019, according to the EFPIA’s survey, which it notes “underlines the importance of scientific research collaboration between the UK and EU.”

“The survey underlines the scale of the task ahead,” noted EFPIA director general Nathalie Moll. “For life saving and life improving medicines, the EU and UK cannot afford to wait any longer to ensure that the necessary cooperation on medicines is in place from the day the UK leaves the EU.

“Securing ongoing cooperation on medicines regulation between the UK and EU is the best way of ensuring that patients across Europe continue to have access to safe and effective medicines.”

The call comes hot on the heels of a warning by UK think-tank The Nuffield Trust that leaving the EU without a deal would risk a “chaotic disruption” to the medicines supply chain, and a rise in prices that would push hospitals deeper into deficit.

 

Big pharma warns ‘no deal’ on Brexit will put drug supply at risk

The Times, Alex Ralph, 9 November 2017

 

The supply of thousands of medicines could be disrupted if Britain leaves the European Union without a deal, drugs companies have warned.

More than 2,600 products have some stage of their manufacture in Britain. Forty-five million patient packs are supplied to other European countries each month, while 37 million move the other way, a survey by the European Federation of Pharmaceutical Industries and Associations (EFPIA) has found.

The results, which underlined the extent of integration across the European drugs industry, showed that about 1,500 clinical trials being conducted in the EU have a UK-based sponsor and that 1,300 EU-authorised products are tested and released from the UK.

Astrazeneca yesterday said that it was having to put in place contingency plans for the “prospect of a hard Brexit”, including duplicating its drugs-testing processes on both sides of the Channel. “The goal is to make sure we do not have any interruption in our supply of medicines to patients,” Pascal Soriot, its chief executive, said. The preparation “to get ready for all options” follows similar planning by Glaxosmithkline, which said last month that it was “putting facilities on both sides” and that spending on Brexit would begin “really from the end of the year”.

The regulation of medicines is handled by the European Medicines Agency, which is expected to move from London to the continent.

Drugs companies are concerned about the potential cost and burden of additional regulation when Britain formally leaves the EU, as well as delays to supply. The survey found that 45 per cent of members expected “trade delays if the UK and Europe fell back to World Trade Organisation rules”.

Nathalie Moll, director general of EFPIA, said: “For lifesaving and life-improving medicines, the EU and UK cannot afford to wait any longer to ensure that the necessary cooperation on medicines is in place from the day the UK leaves the EU.”

HDA UK Media And Political Bulletin – 10 November 2017

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?